Newswire (Published: Thursday, October 10, 2019, Received: Thursday, October 10, 2019, 4:05:44 PM CDT)

Word Count: 450

2019 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Daily News -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Melbourne, Australia, by NewsRx correspondents, research stated, “Radiolabelled small molecules for imaging prostate cancer have rapidly emerged over the last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (Ga-PSMA11), the most widely used. However, the current evidence-based guidelines for management of prostate cancer were established using computed tomography (CT), magnetic resonance imaging (MRI) and bone scan, despite their limitations.”

Our news journalists obtained a quote from the research from Peter MacCallum Cancer Center, “Prostate-specific-membrane antigen (PSMA) positron-emission tomography (PET)/CT, however, has higher sensitivity and specificity and can lead to both upstaging and downstaging and subsequent changes in management of prostate cancer. The literature for PSMA PET/CT is mostly in the setting of biochemical recurrence and primary staging of intermediate-to-high-risk prostate cancer. Preliminary studies also suggest that there may be a role in nonmetastatic castrate-resistant prostate cancer (nmCRPC) and possibly response to therapy. Despite high sensitivity and specificity, PSMA PET/CT as a single modality for staging advanced prostate cancer is suboptimal, given the low PSMA expression in this subgroup and the complementary role of fluorodeoxyglucose (FDG) PET/CT is required. This is also true in early-stage prostate adenocarcinoma with neuroendocrine differentiation or small-/large-cell neuroendocrine tumours of the prostate. Lack of a globally accepted standardized reporting system for PSMA PET/CT is a current limitation. This is essential to pave the way to incorporating this invaluable molecular imaging modality in clinical trials to assess its impact on outcome, particularly when upstaging or downstaging conventionally imaged disease.”

According to the news editors, the research concluded: “This would then lead to recognition by healthcare providers, incorporation into guidelines for management of prostate cancer and routine use in clinical practice.”

For more information on this research see: Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Therapeutic Advances In Medical Oncology, 2019;11():175883591987682. (Sage Publications - http://www.sagepub.com/; Therapeutic Advances In Medical Oncology - tam.sagepub.com)

The news correspondents report that additional information may be obtained from R. Alipour, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center, Level 5, 305 Grattan Street, Melbourne, VIC 3000, Australia. Additional authors for this research include A. Azad and M.S Hofman.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1177/1758835919876828. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Industries

Healthcare
      Medical Devices
            Medical Diagnostic Equipment
                  Medical Imaging Equipment
Biotechnology
      Biopharmaceuticals
Pharmaceuticals
      Biopharmaceuticals
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Diagnostic Equipment
                        Medical Imaging Equipment

Places

Australia and New Zealand
Australia
Oceania
Melbourne

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies